Published January 1, 2020
| Version v1
Journal article
Open
Design and synthesis of novel peptidomimetics for cancer immunotherapy
Creators
- 1. Istanbul Tech Univ, Dept Chem, TR-34469 Istanbul, Turkey
- 2. Bezmialem Vakif Univ, Comp Aided Drug Discovery Lab, Dept Pharmacol, Fac Pharm, TR-34093 Istanbul, Turkey
- 3. Hacettepe Univ, Canc Inst, Dept Basic Oncol, TR-06100 Ankara, Turkey
- 4. TUBITAK, Marmara Res Ctr, Mat Inst, TR-41470 Kocaeli, Turkey
Description
Tumor cells benefit from some certain signals, which are referred to as "immune checkpoints", to escape immune-mediated destruction. With that in mind, it is believed that the blockade of these points, such as programmed cell death Ligand-1 (PD-L1) and programmed cell death 1 (PD-1), can restore an adaptative immune response against tumoral cells. In this study, we have designed and synthesized some novel peptidomimetics with a 2-aminobenzathiazole scaffold, which targets the PD-1/PDL-1 pathway. In the viability assay, it was found that these compounds decreased the proliferation of peripheral blood mononuclear cells in the concentration of 10 uM. Overall, our results indicate that these novel compounds are potential checkpoint inhibitors for cancer immunotherapy.
Files
10-25135-acg-oc-86-20-09-1802.pdf
Files
(1.2 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:37ffe8fff5c8988f9a1d93d9d1d6de0c
|
1.2 MB | Preview Download |